Tags

Type your tag names separated by a space and hit enter

Could cannabidiol be used as an alternative to antipsychotics?
J Psychiatr Res. 2016 09; 80:14-21.JP

Abstract

Schizophrenia is a mental disorder that affects close to 1% of the population. Individuals with this disorder often present signs such as hallucination, anxiety, reduced attention, and social withdrawal. Although antipsychotic drugs remain the cornerstone of schizophrenia treatment, they are associated with severe side effects. Recently, the endocannabinoid system (ECS) has emerged as a potential therapeutic target for pharmacotherapy that is involved in a wide range of disorders, including schizophrenia. Since its discovery, a lot of effort has been devoted to the study of compounds that can modulate its activity for therapeutic purposes. Among them, cannabidiol (CBD), a non-psychoactive component of cannabis, shows great promise for the treatment of psychosis, and is associated with fewer extrapyramidal side effects than conventional antipsychotic drugs. The overarching goal of this review is to provide current available knowledge on the role of the dopamine system and the ECS in schizophrenia, and to discuss key findings from animal studies and clinical trials investigating the antipsychotic potential of CBD.

Authors+Show Affiliations

Department of Neurosciences, Faculty of Medicine, Université de Montréal, Montreal, Quebec H3C 3J7, Canada. Electronic address: marc.fakhoury@umontreal.ca.

Pub Type(s)

Journal Article
Review
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27267317

Citation

Fakhoury, Marc. "Could Cannabidiol Be Used as an Alternative to Antipsychotics?" Journal of Psychiatric Research, vol. 80, 2016, pp. 14-21.
Fakhoury M. Could cannabidiol be used as an alternative to antipsychotics? J Psychiatr Res. 2016;80:14-21.
Fakhoury, M. (2016). Could cannabidiol be used as an alternative to antipsychotics? Journal of Psychiatric Research, 80, 14-21. https://doi.org/10.1016/j.jpsychires.2016.05.013
Fakhoury M. Could Cannabidiol Be Used as an Alternative to Antipsychotics. J Psychiatr Res. 2016;80:14-21. PubMed PMID: 27267317.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Could cannabidiol be used as an alternative to antipsychotics? A1 - Fakhoury,Marc, Y1 - 2016/05/28/ PY - 2016/03/04/received PY - 2016/04/27/revised PY - 2016/05/26/accepted PY - 2016/6/9/entrez PY - 2016/6/9/pubmed PY - 2017/9/9/medline KW - Antipsychotics KW - Cannabidiol KW - Endocannabinoid system KW - Psychosis KW - Schizophrenia SP - 14 EP - 21 JF - Journal of psychiatric research JO - J Psychiatr Res VL - 80 N2 - Schizophrenia is a mental disorder that affects close to 1% of the population. Individuals with this disorder often present signs such as hallucination, anxiety, reduced attention, and social withdrawal. Although antipsychotic drugs remain the cornerstone of schizophrenia treatment, they are associated with severe side effects. Recently, the endocannabinoid system (ECS) has emerged as a potential therapeutic target for pharmacotherapy that is involved in a wide range of disorders, including schizophrenia. Since its discovery, a lot of effort has been devoted to the study of compounds that can modulate its activity for therapeutic purposes. Among them, cannabidiol (CBD), a non-psychoactive component of cannabis, shows great promise for the treatment of psychosis, and is associated with fewer extrapyramidal side effects than conventional antipsychotic drugs. The overarching goal of this review is to provide current available knowledge on the role of the dopamine system and the ECS in schizophrenia, and to discuss key findings from animal studies and clinical trials investigating the antipsychotic potential of CBD. SN - 1879-1379 UR - https://www.unboundmedicine.com/medline/citation/27267317/Could_cannabidiol_be_used_as_an_alternative_to_antipsychotics L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-3956(16)30104-2 DB - PRIME DP - Unbound Medicine ER -